Get alerts for new trials in your area by subscribing now
Pulmonary hypertension is raised blood pressure in the arteries that carry blood from the heart to the lungs. Over time the right side of the heart has to pump harder against that pressure, and it can weaken and fail. Symptoms come on slowly: breathlessness with activity, tiredness, chest pressure, dizziness or fainting, and swelling in the ankles or belly. Because these signs look like asthma, heart disease, or simply being out of shape, the diagnosis is often delayed. It is suspected on an echocardiogram and confirmed by right heart catheterization, which measures the pressure directly.
Doctors sort pulmonary hypertension into five groups by cause, and the group decides the treatment. Group 1 is pulmonary arterial hypertension, or PAH, a rare disease of the small lung arteries themselves, which can be idiopathic, inherited, or linked to conditions such as scleroderma. Group 2, the most common, comes from left sided heart disease; group 3 from lung diseases such as COPD and pulmonary fibrosis; group 4 from old blood clots in the lungs, which surgery can sometimes cure; and group 5 from other or mixed causes. Most PAH medicines are approved only for group 1, which is why most drug trials enroll people with PAH.
New drug class trials. Medicines that target the cell overgrowth narrowing the lung arteries, following sotatercept, tested on top of standard treatment in Phase 2.
Combination and earlier treatment trials. Whether starting several medicines at once, or a new drug soon after diagnosis, changes the course of PAH.
Device and procedure trials. Catheter procedures that quiet the nerves around the pulmonary artery, compared with a sham procedure; see medical device clinical trials.
Inhaled treatment trials. Inhaled forms of existing medicines, including for pulmonary hypertension linked to lung disease.
Biomarker and natural history studies. Blood tests and imaging that predict who will worsen, often enrolling people at any stage.
Pediatric studies. Research in infants and children, including babies born early with lung disease and pulmonary hypertension.
Most drug trials enroll adults, often 18 to 80, with PAH confirmed by right heart catheterization, who are on stable background treatment and in a set functional class, usually able to walk a measured distance in six minutes. Some trials are designed for people diagnosed within the past year; others for people still limited despite two or three medicines. Device trials have their own anatomy and pressure requirements. Pulmonary hypertension from heart or lung disease is studied in separate trials, and pediatric studies enroll infants and children with a parent's consent. Eligibility always varies by study.
Group 1, PAH. Disease of the small lung arteries; the target of most drug trials, which ask for catheterization results.
Groups 2 and 3. Pulmonary hypertension from left heart disease or lung disease; studied in their own, fewer trials.
Group 4, CTEPH. Caused by old clots; may be treated with surgery or balloon procedures, and studied separately.
Functional class I to IV. How much daily activity is limited, from none to symptoms at rest. Trials often require class II or III.
Identify your trial. Use the filters and search "pulmonary arterial hypertension" and "PAH" as well as "pulmonary hypertension." Titles say which group the study enrolls.
Select your preferred location. Enter your city or state. Most trials run at pulmonary hypertension centers, and many sponsors help with travel.
Explore study details. Click "Learn More" for the group, functional class, background medicines required, and the six minute walk test.
Complete the health profile. Click "Get started" to begin the 5-step application. Have ready your diagnosis and group, your latest right heart catheterization results, and your current medicines.
Submit the application. A clinical trial coordinator reviews it and contacts you. Nothing is decided until informed consent, and participation is voluntary at every step.